The nucleus accumbens (NAc), also known as the accumbens nucleus, is a key component of the ventral striatum and plays a critical role in the brain's reward, motivation, and motor coordination systems. It is centrally involved in neurodegenerative diseases, particularly Parkinson's disease and Alzheimer's disease. [1]
The nucleus accumbens is located in the basal forebrain, situated at the intersection of the caudate nucleus and putamen (forming the striatum). It is divided into two primary subregions: [2]
The NAc receives dense dopaminergic inputs from the ventral tegmental area via the mesolimbic pathway. It also receives glutamatergic inputs from: [3]
The nucleus projects to: [4]
The nucleus accumbens is significantly affected in Parkinson's disease due to its rich dopaminergic innervation. Key implications include: [5]
Dopaminergic Degeneration: Loss of dopaminergic neurons in the substantia nigra pars compacta reduces dopamine signaling to the NAc, contributing to:
Motor and Non-Motor Symptoms: The NAc plays a role in both motor execution (via connections to motor circuits) and non-motor symptoms (reward processing deficits).
Levodopa-Induced Dyskinesias: The nucleus accumbens is implicated in the development of levodopa-induced dyskinesias, as dopaminergic stimulation of this region can lead to abnormal involuntary movements.
While primarily considered a dopaminergic region, the NAc shows involvement in Alzheimer's disease: [6]
Amyloid Deposition: Studies have shown amyloid-beta plaques in the nucleus accumbens in AD patients.
Cholinergic Deficits: The basal forebrain cholinergic system, which projects to the NAc, is compromised in AD, affecting learning and memory processes associated with reward.
Neuropsychiatric Symptoms: NAc dysfunction contributes to depression, apathy, and anhedonia commonly observed in AD patients.
The NAc expresses high levels of dopamine receptors:
The COMT (catechol-O-methyltransferase) enzyme is highly expressed in the prefrontal cortex and regulates dopamine levels in the NAc. COMT polymorphisms affect:
The nucleus accumbens has been explored as a DBS target for:
Drugs targeting the NAc include: